Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 322

1.

Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration.

Smith WW, Pei Z, Jiang H, Moore DJ, Liang Y, West AB, Dawson VL, Dawson TM, Ross CA.

Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18676-81. Epub 2005 Dec 13.

2.

LRRK2 and parkin immunoreactivity in multiple system atrophy inclusions.

Huang Y, Song YJ, Murphy K, Holton JL, Lashley T, Revesz T, Gai WP, Halliday GM.

Acta Neuropathol. 2008 Dec;116(6):639-46. doi: 10.1007/s00401-008-0446-3. Epub 2008 Oct 21.

PMID:
18936941
3.

Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein.

Lin X, Parisiadou L, Gu XL, Wang L, Shim H, Sun L, Xie C, Long CX, Yang WJ, Ding J, Chen ZZ, Gallant PE, Tao-Cheng JH, Rudow G, Troncoso JC, Liu Z, Li Z, Cai H.

Neuron. 2009 Dec 24;64(6):807-27. doi: 10.1016/j.neuron.2009.11.006.

4.

LRRK2 and neurodegeneration.

Santpere G, Ferrer I.

Acta Neuropathol. 2009 Mar;117(3):227-46. doi: 10.1007/s00401-008-0478-8. Epub 2009 Jan 14. Review.

PMID:
19142648
5.

Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells.

Plowey ED, Cherra SJ 3rd, Liu YJ, Chu CT.

J Neurochem. 2008 May;105(3):1048-56. doi: 10.1111/j.1471-4159.2008.05217.x. Epub 2008 Jan 7.

6.

Leucine-Rich Repeat Kinase 2 interacts with Parkin, DJ-1 and PINK-1 in a Drosophila melanogaster model of Parkinson's disease.

Venderova K, Kabbach G, Abdel-Messih E, Zhang Y, Parks RJ, Imai Y, Gehrke S, Ngsee J, Lavoie MJ, Slack RS, Rao Y, Zhang Z, Lu B, Haque ME, Park DS.

Hum Mol Genet. 2009 Nov 15;18(22):4390-404. doi: 10.1093/hmg/ddp394. Epub 2009 Aug 19.

PMID:
19692353
7.

Leucine-rich repeat kinase 2 induces alpha-synuclein expression via the extracellular signal-regulated kinase pathway.

Carballo-Carbajal I, Weber-Endress S, Rovelli G, Chan D, Wolozin B, Klein CL, Patenge N, Gasser T, Kahle PJ.

Cell Signal. 2010 May;22(5):821-7. doi: 10.1016/j.cellsig.2010.01.006. Epub 2010 Jan 13.

8.

[Clinical molecular genetics for PARK8 (LRRK2)].

Tomiyama H, Hatano T, Hattori N.

Brain Nerve. 2007 Aug;59(8):839-50. Review. Japanese.

PMID:
17713120
9.

What genetics tells us about the causes and mechanisms of Parkinson's disease.

Corti O, Lesage S, Brice A.

Physiol Rev. 2011 Oct;91(4):1161-218. doi: 10.1152/physrev.00022.2010. Review.

10.

Parkin and defective ubiquitination in Parkinson's disease.

Dawson TM.

J Neural Transm Suppl. 2006;(70):209-13. Review.

PMID:
17017531
11.

A Drosophila model for LRRK2-linked parkinsonism.

Liu Z, Wang X, Yu Y, Li X, Wang T, Jiang H, Ren Q, Jiao Y, Sawa A, Moran T, Ross CA, Montell C, Smith WW.

Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2693-8. doi: 10.1073/pnas.0708452105. Epub 2008 Feb 7.

12.

Mechanisms in dominant parkinsonism: The toxic triangle of LRRK2, alpha-synuclein, and tau.

Taymans JM, Cookson MR.

Bioessays. 2010 Mar;32(3):227-35. doi: 10.1002/bies.200900163.

14.

Synphilin-1 attenuates mutant LRRK2-induced neurodegeneration in Parkinson's disease models.

Liu J, Li T, Thomas JM, Pei Z, Jiang H, Engelender S, Ross CA, Smith WW.

Hum Mol Genet. 2016 Feb 15;25(4):672-80. doi: 10.1093/hmg/ddv504. Epub 2016 Jan 6.

15.

Conditional expression of Parkinson's disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegeneration.

Tsika E, Kannan M, Foo CS, Dikeman D, Glauser L, Gellhaar S, Galter D, Knott GW, Dawson TM, Dawson VL, Moore DJ.

Neurobiol Dis. 2014 Nov;71:345-58. doi: 10.1016/j.nbd.2014.08.027. Epub 2014 Aug 29.

16.

G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies.

Gaig C, Martí MJ, Ezquerra M, Rey MJ, Cardozo A, Tolosa E.

J Neurol Neurosurg Psychiatry. 2007 Jun;78(6):626-8. Epub 2007 Jan 8.

17.

Prevalence and clinical features of LRRK2 mutations in patients with Parkinson's disease in southern Spain.

Gao L, Gómez-Garre P, Díaz-Corrales FJ, Carrillo F, Carballo M, Palomino A, Díaz-Martín J, Mejías R, Vime PJ, López-Barneo J, Mir P.

Eur J Neurol. 2009 Aug;16(8):957-60. doi: 10.1111/j.1468-1331.2009.02620.x. Epub 2009 Mar 31.

PMID:
19473361
18.

Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson's disease cell and mouse models.

Li T, Yang D, Zhong S, Thomas JM, Xue F, Liu J, Kong L, Voulalas P, Hassan HE, Park JS, MacKerell AD Jr, Smith WW.

Hum Mol Genet. 2014 Dec 1;23(23):6212-22. doi: 10.1093/hmg/ddu341. Epub 2014 Jul 3.

PMID:
24993787
19.

(R1441C) LRRK2 induces the degeneration of SN dopaminergic neurons and alters the expression of genes regulating neuronal survival in a transgenic mouse model.

Weng YH, Chen CY, Lin KJ, Chen YL, Yeh TH, Hsiao IT, Chen IJ, Lu CS, Wang HL.

Exp Neurol. 2016 Jan;275 Pt 1:104-15. doi: 10.1016/j.expneurol.2015.09.001. Epub 2015 Sep 10.

PMID:
26363496
20.

The familial Parkinsonism gene LRRK2 regulates neurite process morphology.

MacLeod D, Dowman J, Hammond R, Leete T, Inoue K, Abeliovich A.

Neuron. 2006 Nov 22;52(4):587-93.

Supplemental Content

Support Center